Citi Sticks to Its Sell Rating for Blueprint Medicines (BPMC)
In a report released today, David Lebowitz from Citi reiterated a Sell rating on Blueprint Medicines (BPMC – Research Report), with a price target of $83.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Lebowitz is a 3-star analyst with an average return of 1.6% and a 51.33% success rate. Lebowitz covers the Healthcare sector, focusing on stocks such as Exelixis, Alnylam Pharma, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $125.50 average price target.
Based on Blueprint Medicines’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $149.41 million and a net profit of $496 thousand. In comparison, last year the company earned a revenue of $96.12 million and had a net profit of $89.14 million
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in March 2025, Jeffrey Albers, a Director at BPMC sold 5,766.00 shares for a total of $512,020.80.
Read More on BPMC:
Disclaimer & DisclosureReport an Issue
- Blueprint Medicines downgraded to Sector Perform from Outperform at Scotiabank
- Blueprint Medicines downgraded to Hold from Buy at Needham
- Morning Movers: Trump to bump steel tariffs, pharma companies announce deals
- Blueprint Medicines downgraded to Neutral from Outperform at Wedbush
- Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA
